Search the Newsreel

Traws Pharma Expects Q3 Resubmission for Flu Antiviral

Traws Pharma (TRAW) investor Squadron reports 0% beneficial ownership in 13G/A

Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank have filed an amended Schedule 13G (Amendment No. 4) for Traws Pharma (TRAW), reporting 0% beneficial ownership. The group now holds no shares of Traws Pharma common stock and possesses no …

Sirenia Capital (TRAW) discloses warrant-based stake capped at 9.9% ownership

Sirenia Capital Management LP and Alex Silverstein have disclosed a beneficial ownership stake in Traws Pharma, Inc. (TRAW) through warrants. The Sirenia-managed funds hold warrants exercisable for 6,565,474 shares of common stock, but their actual beneficial ownership is capped at 9.9% due to a …

Strawbear Entertainment Sets Date to Approve Interim Results and Consider Dividend

Adage Capital reports 4.79% Traws Pharma (TRAW) stake totaling 730,000 shares

Adage Capital Management, L.P. and its affiliates, including Robert Atchinson and Phillip Gross, have reported a beneficial ownership of 730,000 shares of Traws Pharma, Inc. common stock, representing 4.79% of the outstanding shares. This information was disclosed in a Schedule 13G/A filing, indicating a …

Strawberry Fields REIT (NYSEAMERICAN:STRW) Price Target Raised to $16.00

Traws Pharma Inc (TRAW) Stock News Today

This article provides the current stock information for Traws Pharma Inc (TRAW), including its stock price, market cap, and a note that more news is coming soon. As of the time of publication, TRAW is trading at $0.545, up 2.44%, with a market cap …

Strawberry Fields REIT (STRW) Stock Drifts As Steady Cash Flow Masks Leverage Risk

Traws Pharma Inc (TRAW) Earnings Forecast: Future EPS & Revenue Growth Estimates

Traws Pharma Inc (TRAW) has an earnings forecast score of 6.00, placing it 330 out of 387 in the Biotechnology & Medical Research industry. The average analyst price target for TRAW is $8.00, with all analysts suggesting a "Hold" rating. The previous quarter's EPS …

Earnings call transcript: Strawberry Fields REIT posts mixed Q2 2026 results

Strawberry Fields REIT, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:STRW) 2026-08-07

Earnings To Watch: Strawberry Fields REIT Inc (STRW) Q2 2026 -- GF Value Sees 41% Downside

Strawberry Fields REIT Declares Third-Quarter Cash Dividend

Strawberry Fields REIT, Inc. (STRW) Q2 FFO and Revenues Lag Estimates

Strawberry Fields REIT (NYSEAMERICAN:STRW) Issues Earnings Results

Traws Pharma Receives Nasdaq Minimum Bid Price Notice

Traws Pharma (TRAW) has received a notice from Nasdaq for failing to maintain the minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 days, until January 25, 2027, to regain compliance, with a possibility of a second …

Traws Pharma Inc (TRAW) Valuation: PE, PB & Fair Value Analysis

Traws Pharma Inc (TRAW) has a current valuation score of 9.42, placing it 17th out of 384 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.25, significantly below its recent high and above its recent low. Key valuation metrics …

Traws Pharma, Inc. Revenue Breakdown – NASDAQ:TRAW

Traws Pharma, Inc. (NASDAQ:TRAW) generated $2.79 million USD in revenue last year, primarily from its Oncology Therapeutics segment. This represents a significant increase compared to $226,000 USD in the previous year. The United States was the company's largest regional contributor, accounting for all of …

Traws Pharma Received Notice of Noncompliance

Traws Pharma (TRAW) has received a notice of noncompliance from Nasdaq due to its stock trading below the minimum $1.00 bid price requirement for 30 consecutive business days. The company has until January 25, 2027, to regain compliance, with a possibility of an extension …

Traws Pharma Inc (TRAW) Financial Health: Profitability & Balance Sheet Analysis

Traws Pharma Inc (TRAW) currently holds a financial score of 9.52, ranking 2nd in the Biotechnology & Medical Research industry, indicating robust financial health and high operating efficiency. Despite this strong ranking, the company experienced a 100.00% year-over-year decrease in its latest quarterly revenue …

Strawberry Fields REIT (STRW) Projected to Announce Quarterly Earnings on Thursday

TRAW|Traws Pharma Inc|Price:0.490|Chg%:+0.008

Traws Pharma Inc (TRAW) is a clinical-stage biopharmaceutical company focused on developing therapies for respiratory viral diseases and oncology. Its stock shows strong fundamentals and growth potential, despite recent market underperformance, with analysts currently rating it as a "Hold" with a target price of …

Traws Pharma Inc (TRAW) Institutional Confidence

This article provides an overview of Traws Pharma Inc's (TRAW) institutional confidence score and shareholder activity as of July 28, 2026. It details the shares held and percentage change for several institutional investors, highlighting significant increases by Ikarian Capital LLC and Adage Capital Management, …

TRAW|Traws Pharma Inc|Price:0.488|

This article provides a detailed overview of Traws Pharma Inc (TRAW), a clinical-stage biopharmaceutical company focusing on novel therapies for respiratory viral diseases and oncology. It highlights the company's background, business scope, key clinical programs including Tivoxavir marboxil and Ratutrelvir, and outlines financial data …

Traws Pharma Inc (TRAW) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividends and stock splits for Traws Pharma Inc (TRAW). It notes that no dividends have been distributed in the past five years and lists several merger-type stock splits from 2021 and 2024. The stock information also includes …

Traws Pharma Inc (TRAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Traws Pharma Inc (TRAW), detailing its business segments and regional revenue contributions. As of the reported data, the company shows 0.00% revenue from its Symbio business segment and 0.00% revenue from the United States region. The report …

Traws Pharma Inc (TRAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Traws Pharma Inc (TRAW), detailing its support and resistance levels, indicator readings (MACD, RSI, KDJ, etc.), and moving average signals. TRAW's stock currently ranks 43rd in its industry for price momentum and is trading within a range …

Strawberry Fields REIT (NYSEAMERICAN:STRW) Shares Down 2.1% - Here's Why

Traws Pharma (TRAW) Registration filing Summary

Traws Pharma (TRAW) has filed a registration summary outlining its business model as a clinical-stage biopharmaceutical company focused on antiviral and oncology therapies. The company faces financial challenges, including recurring losses and liquidity concerns, but is seeking to fund its clinical and preclinical programs …

Traws Pharma (TRAW) grants 97,000 stock options to science chief

Traws Pharma, Inc. (TRAW) has granted 97,000 stock options to its Chief Science Officer of Virology, Charles David Pauza. The options, priced at $0.68 per share, are part of a compensation award and will vest 100% on July 9, 2027, with an expiration date …

Traws Pharma (TRAW) grants CFO Parker Nolan 90,000 stock options

Traws Pharma (TRAW) has granted its Chief Financial Officer, Parker Charles Nolan, 90,000 stock options with an exercise price of $0.68 per share. These options will vest completely on July 9, 2027, which is the first anniversary of the grant date, and will expire …

Form 4 Traws Pharma Inc For: 15 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Traws Pharma Inc on July 15th, noting that the company's stock symbol is TRAW and its price increased by 1.47%. The content primarily consists of market data, news headlines, and navigational links, typical …

Traws Pharma (TRAW) awards 274,000 stock options to CEO Dukes

Traws Pharma, Inc. (TRAW) has granted its CEO, Iain D. Dukes, stock options for 274,000 common shares with an exercise price of $0.68 per share. These options, awarded under the company's 2021 Incentive Compensation Plan, will vest 100% on July 9, 2027, and expire …